Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal

Journal of Medical Virology

Volumn 83, Issue 4, 2011, Pages 608-615

  Calado, Rita Almeida ^a,b   Rocha, Maria Raquel ^a   Parreira, Ricardo ^a   Piedade, João ^a   Venenno, Teresa ^a   Esteves, Aida ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

HCV; Intravenous drug users; Portugal; Subtypes

Indexed keywords

VIRUS RNA;

ARTICLE; GENETIC DISTANCE; GENOTYPE; GEOGRAPHIC ORIGIN; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PHYLOGENY; PORTUGAL; PREVALENCE; VIREMIA; VIRUS GENE; VIRUS TYPING;

ADULT; CLUSTER ANALYSIS; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMORPHISM, GENETIC; PORTUGAL; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 79951521752     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21955     Document Type: Article

References (36)

1. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. 2009. The neglected hepatitis C virus genotypes 4, 5 and 6: An international consensus report. Liver Int 30: 342-355.
2. Araújo F, Henriques I, Monteiro F, Meireles E, Cruz A, Tavares G, Mota-Miranda A. 2005. Evaluation of NucliSens-AmpliScreen methodology to detect subtypes G of HIV-1 and 4c/4d of HCV in the screening of blood donors. Transfus Clin Biol 12: 331-335.
3. Badura R, Valente C, Valadas E, Faísca R, Tavares A, Borges F, Alves H, Machado J, Serrão R, Castro RS. 2008. HCV and HCV/HIV in Portugal-a multicentric cohort study. 4th International Workshop in HCV/HIV co-infection, 19-21 June, Madrid, Spain.
4. Carvalho A, Martinho A, Leitão J, Cipriano MA, Coimbra H, Porto A. 2000. HCV genotypes: Liver histopathology and immunologic profile in four groups of patients. Acta Med Port 13: 67-75.
5. Chlabicz S, Flisiak R, Kowalczuk O, Wiercińska-Drapalo A, Pytel-Krolczuk B, Prokopowicz D, Chyczewski L. 2008. High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland. J Med Virol 80: 615-618.
6. Cochrane A, Searle B, Hardie A, Robertson R, Delahooke T, Cameron S, Tedder RS, Dusheiko GM, De Lamballerie X, Simmonds P. 2002. A genetic analysis of hepatitis C virus transmission between injection drug users. J Infect Dis 186: 1212-1221.
7. Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, Bhagani S, Emery VC, Dusheiko GM, Klenerman P. 2008. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 197: 1558-1566.
8. de Bruijne J, Schinkel J, Prins M, Koekkoek SM, Aronson SJ, van Ballegooijen MW, Reesink HW, Molenkamp R, van de Laar TJ. 2009. Emergence of hepatitis C virus genotype 4: Phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol 47: 3832-3838.
9. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Statistical bulletin. 2009. Drug-related infectious diseases (INF)- Prevalence of HIV, HCV and HBV in IDUs. Available at: Accessed on 18-05-2010.
10. Esteban JI, Sauleda S, Quer J. 2008. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48: 148-162.
11. Fernández-Arcás N, López-Siles J, Trapero S, Ferraro A, Ibáñez A, Orihuela F, Maldonado J, Alonso A. 2006. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): Phylogenetic and epidemiological analyses. J Med Virol 78: 1429-1435.
12. Kamal SM, Nasser IA. 2008. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 47: 1371-1383.
13. Katoh K, Asimenos G, Toh H. 2009. Multiple alignment of DNA sequences with MAFFT. Methods Mol Biol 537: 39-64.
14. Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, Tsantoulas D, Vafiadi I, Hatzis G, Skoutelis A, Akriviadis E, Vasiliadis T, Kitis G, Magiorkinis G, Hatzakis A. 2006. Molecular epidemiology of hepatitis C virus (HCV) in Greece: Temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 13: 19-27.
15. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int 29: 74-81.
16. Lee YM, Lin HJ, Chen YJ, Lee CM, Wang SF, Chang KY, Chen TL, Liu HF, Chen YM. 2010. Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form-2b6w. J Med Virol 82: 57-68.
17. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Alias M, Trimoulet P, Chaix ML, Hézode C, Foucher J, Fontaine H, Roque-Afonso AM, Gassin M, Schvoerer E, Gaudy C, Roche B, Doffoël M, D'Alteroche L, Vallet S, Baazia Y, Pozzetto B, Thibault V, Nousbaum JB, Roulot D, Coppere H, Poinard T, Payan C, Izopet J. 2009. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol 81: 2029-2035.
18. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. 2006. Clinical presentation and course of acute hepatitis virus in HIV-infected patients. J Acquir Immune Defic Syndr 41: 31-36.
19. Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, Allain JP, Hatzakis A. 2009. The global spread of hepatitis C virus 1a and 1b: A phylodynamic and phylogeographic analysis. PLoS Med 6: e1000198.
20. Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V. 2008. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. J Viral Hepat 15: 710-715.
21. Micalessi MI, Gérard C, Ameye L, Plasschaert S, Brochier B, Vranckx R. 2008. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005. J Med Virol 80: 640-645.
22. Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butterworth L, Cooksley G, Gish RG, Beaugrand M, Fay F, Fay O, Gonzalez JE, Martins RM, Dhumeaux D, Vanderborght B, Stuyver L, Sablon E, de Lamballerie X, Pawlotsky JM. 2006. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol 78: 1296-1303.
23. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. 2009. HCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 9: 34-47.
24. Pouillot R, Lachenal G, Pybus OG, Rousset D, Njouom R. 2008. Variable epidemic histories of hepatitis C virus genotype 2 infection in West Africa and Cameroon. Infect Genet Evol 8: 676-681.
25. Pybus OG, Cochrane A, Holmes EC, Simmonds P. 2005. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol 5: 131-139.
26. Ramalho F, Costa A, Pires A, Carita P, Serejo F, Pinto Correia A, Fatela N, Glória H, Lopes J, Cortez Pinto H, Marinho R, Raimundo M, Velosa J, Batista A, Carneiro de Moura M. 2000. Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci 45: 182-187.
27. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182: 698-707.
28. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85: 3173-3188.
29. Sulkowski MS. 2008. Viral hepatitis and HIV coinfection. J Hepatol 48: 353-667.
30. Sulkowski MS, Thomas DL. 2003. Hepatitis C in the HIV-infected patient. Clin Liver Dis 7: 179-194.
31. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
32. Thomas DL. 2008. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 59: 473-485.
33. van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, Rezza G, Broers B, Robertson JR, Brettle RP, McMenamin J, Prins M, Cochrane A, Simmonds P, Coutinho RA, Bruisten S, European and Italian Seroconverter Studies. 2004. Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis. J Infect Dis 189: 292-302.
34. van de Laar TJ, Langendam MW, Bruisten SM, Welp EA, Verhaest I, van Ameijden EJ, Coutinho RA, Prins M. 2005. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol 77: 509-518.
35. Weinstock DM, Merrick S, Malak SA, Jacobs J, Sepkowitz KA. 1999. Hepatitis C in an urban population infected with the human immunodeficiency virus. AIDS 13: 2593-2595.
36. Weissenbacher M, Rossi D, Radulich G, Sosa-Estáni S, Vila M, Vivas E, Avila MM, Cuchi P, Rey J, Peralta LM. 2003. High prevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dis 37: S348-S352.